[{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"Atherogenic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GREECE","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GREECE","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"National Jewish Health | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Colorado, Denver \/ National Jewish Health | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ National Jewish Health | US Department of Defense"},{"orgOrder":0,"company":"Texas Tech University","sponsor":"Kyowa Hakko Bio","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Texas Tech University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University \/ Kyowa Hakko Bio","highestDevelopmentStatusID":"1","companyTruncated":"Texas Tech University \/ Kyowa Hakko Bio"}]

Find Clinical Drug Pipeline Developments & Deals for Citrulline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anemia, Sickle Cell.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          May 25, 2025

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Colorado, Denver

                          Country arrow
                          FNCE
                          Not Confirmed

                          University of Colorado, Denver

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          March 02, 2022

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : National Jewish Health | US Department of Defense

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Septal Defects, Ventricular.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          February 23, 2022

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The Phase 1 safety study will test the safest maximum dose of L-citrulline for patients with MELAS. Once established, this dose will be used in a future clinical trial that will test the efficacy of L-citrulline.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          April 29, 2021

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Vaso-Occlusive Crises.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          April 21, 2021

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Texas Tech University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Texas Tech University

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Kyowa Hakko Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Asklepion Pharmaceuticals

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : L-Citrulline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Insufficiency.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          September 30, 2020

                          Lead Product(s) : Citrulline

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank